Dr. Ravi Braich has a chemistry background and is a partner in the Patent practice group. He focuses his practice on U.S. and foreign patent prosecution, opinion work, and counseling clients in the areas of chemicals, diagnostics, therapeutics, pharmaceuticals, biotechnology, and the life sciences.
I focus my practice on helping clients, including hospitals, research institutes, and small and medium-sized companies, devise and pursue effective strategies for protecting their breakthrough technologies. I have experience in a wide range of technologies, including small molecules, nucleic acid-based technologies (RNAi, activating RNAs, antisense nucleic acids, and microRNAs), peptides, antibodies, prodrugs and drug conjugates, anesthetics, diagnostic/imaging agents, antiviral agents, cancer vaccines, semi-conductor materials, drug targeting and drug delivery, microfluidic devices, drug delivery devices, diagnostic devices, and biomimetic devices. This work involves their synthesis, purification, and use.
I focus on strategic patent counseling and prosecution in the areas of chemicals, diagnostics, therapeutics, and pharmaceuticals in all phases of development, within and outside the United States.
I work closely with corporations, universities, and licensee counsel on strategic management and growth of their patent portfolios.
I work with clients in varieties of industries to conduct patentability and freedom to operate analysis and competitive intelligence and analysis in areas of small molecules, nucleic acids, polymers, and diagnostic methods and devices.
I counsel clients on how the new European Union Unitary Patent and the opening of the Unified Patent Court (UPC) will affect all pending European applications and patents.
Unless the Supreme Court reverses the “full scope” requirement, I expect to see more challenges to patents based on the written description/enablement requirements, not only in the chemical and biotechnology spaces but also in the high-tech space.
This article featuring partner-level promotions in the first quarter of 2023 mentions Chicago Project Finance & Public Finance partner Julie Seymour’s appointment to NP’s Management Committee. The article also highlights members of the 2023 new partner class: Boston Intellectual Property partner Ravi Braich; Long Island Healthcare partner Jason Chimon; Washington, DC Community Development Finance partner Emily McKinney; New York City Complex Disputes partner Alper Tosun; and Affordable Housing & Real Estate partners Julia Casteleiro, Ari Glatt, and Kathie Soroka of New York and Ian O’Banion from San Francisco.
This article spotlights the 2023 new partner class, which includes Long Island Healthcare partner Jason Chimon; Boston Intellectual Property partner Ravi Braich; New York City Complex Disputes partner Alper Tosun; Affordable Housing & Real Estate partners Julia Casteleiro, Ari Glatt, and Kathie Soroka of New York and Ian O’Banion from San Francisco; and Washington, DC Community Development Finance partner Emily McKinney. The article also quotes CEO and Managing Partner Steve Zubiago.
McGill University, Ph.D., Chemistry
Suffolk University Law School, J.D., cum laude
University of Toronto, B.Sc., Biochemistry
Subscribe to stay informed of the latest legal news, alerts, and business trends.Subscribe